Explore

Trendline Trendline
Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development

Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development

Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development
Trendline Trendline
Biotech Companies Secure Major Funding to Advance Cancer Treatments

Biotech Companies Secure Major Funding to Advance Cancer Treatments

Biotech Companies Secure Major Funding to Advance Cancer Treatments
Reuters Reuters
Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

By Manya Saini April 17 (Reuters) - Weight-loss drug developer Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut on Friday after closing a $625 million U.S. initial public offering, as Wall Street's appetite for the fast-growing market remains unsated.
Trendline Trendline
Beeline Secures $300 Million for Immunology Drug Development

Beeline Secures $300 Million for Immunology Drug Development

Beeline Secures $300 Million for Immunology Drug Development
Trendline Trendline
Enveric Biosciences Secures $13.9 Million Private Placement for Therapeutic Development

Enveric Biosciences Secures $13.9 Million Private Placement for Therapeutic Development

Enveric Biosciences Secures $13.9 Million Private Placement for Therapeutic Development
Trendline Trendline
Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq

Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq

Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq
Trendline Trendline
Veralto Corporation Announces First Quarter 2026 Earnings Call for Investors

Veralto Corporation Announces First Quarter 2026 Earnings Call for Investors

Veralto Corporation Announces First Quarter 2026 Earnings Call for Investors
Trendline Trendline
Astellas Pharma to Close Universal Cells' Seattle Office, Affecting 50 Employees

Astellas Pharma to Close Universal Cells' Seattle Office, Affecting 50 Employees

Astellas Pharma to Close Universal Cells' Seattle Office, Affecting 50 Employees
Trendline Trendline
TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment

TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment

TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment
Trendline Trendline
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence
Trendline Trendline
Zealand Pharma Appoints Eric Rojas as Vice President to Strengthen Investor Relations

Zealand Pharma Appoints Eric Rojas as Vice President to Strengthen Investor Relations

Zealand Pharma Appoints Eric Rojas as Vice President to Strengthen Investor Relations
Trendline Trendline
Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation